Citizens Financial Group Inc. RI Has $1.22 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Citizens Financial Group Inc. RI lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 1.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 14,154 shares of the company’s stock after selling 147 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Novo Nordisk A/S were worth $1,218,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Center for Financial Planning Inc. boosted its holdings in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares during the period. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth $28,000. Albion Financial Group UT boosted its holdings in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares during the last quarter. Finally, Hager Investment Management Services LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $46,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on NVO shares. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $74.75 on Thursday. The stock has a market cap of $335.42 billion, a P/E ratio of 22.72, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a fifty day moving average price of $84.39 and a two-hundred day moving average price of $103.83. Novo Nordisk A/S has a one year low of $73.80 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.